Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
주식 순위 #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
주가
$9.60
마지막 동기화: 2025-05-21
시가총액
$1.08B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 OptiNose, Inc. (OPTN)

카테고리

OptiNose, Inc. (OPTN)의 매출
Mar 2025 기준 매출 TTM: $81.86M
OptiNose, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $81.86M입니다. 2023년에 회사는 $70.99M의 수익을 올렸으며 이는 2022년의 $76.28M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
OptiNose, Inc.의 수익 기록 (2015 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $81.86M 4.64%
2024 $78.23M 10.20%
2023 $70.99M -6.93%
2022 $76.28M 2.18%
2021 $74.65M 51.99%
2020 $49.12M 41.83%
2019 $34.63M 390.18%
2018 $7.07M 0.00%
2017 0.00 -100.00%
2016 $47.50M 55,782.35%
2015 $85.00K 0.00%
유사 기업 또는 경쟁사의 매출